Literature DB >> 17238025

Role of infection in irritable bowel syndrome.

Robin C Spiller1.   

Abstract

Infection by pathogenic organisms leads to mucosal damage and disruption of the gut's extensive commensal flora, factors which may lead to prolonged bowel dysfunction. Six to 17% of unselected irritable bowel syndrome (IBS) patients believe their symptoms began with an infection, which is supported by prospective studies showing a 4%-31% incidence of postinfectious IBS-(PI) following bacterial gastroenteritis. The wide range of incidence can be accounted for by differences in risk factors, which include in order of magnitude; severity of initial illness > bacterial toxigenicity > hypochondriasis, depression and neuroticism, and adverse life events in the previous 3 months. PI-IBS has been reported after Campylobacter, Salmonella, and Shigella infections. Serial biopsies after Campylobacter jejuni gastroenteritis show an initial inflammatory infiltrate, with an increase in enterochromaffin (EC) cells, which in most cases subsides over the next 6 months. Those who go on to develop IBS show increased numbers of EC and lymphocyte cell counts at 3 months compared with those who do not develop IBS. Interleukin-1beta mRNA levels are increased in the mucosa of those who develop PI-IBS, who also show increased gut permeability. Recover can be slow, with approximately 50% still having symptoms at 5 years. Recent studies suggest an increase in peripheral blood mononuclear cell cytokine production in unselected IBS, an abnormality that may be ameliorated by probiotic treatment. The role of small-bowel bacterial overgrowth in IBS is controversial, but broad-spectrum antibiotics do have a temporary benefit in some patients. More acceptable long-term treatments altering gut flora are awaited with interest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17238025     DOI: 10.1007/s00535-006-1925-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  46 in total

1.  Antibiotics increase functional abdominal symptoms.

Authors:  P R Maxwell; E Rink; D Kumar; M A Mendall
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

Review 2.  Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.

Authors:  Robert Penner; Richard N Fedorak; Karen L Madsen
Journal:  Curr Opin Pharmacol       Date:  2005-10-07       Impact factor: 5.547

Review 3.  Review article: epidemiology and quality of life in functional gastrointestinal disorders.

Authors:  L Chang
Journal:  Aliment Pharmacol Ther       Date:  2004-11       Impact factor: 8.171

4.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

5.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

7.  Terminal ileal mucosal mast cells in irritable bowel syndrome.

Authors:  A P Weston; W L Biddle; P S Bhatia; P B Miner
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

8.  A placebo-controlled trial of itopride in functional dyspepsia.

Authors:  Gerald Holtmann; Nicholas J Talley; Tobias Liebregts; Birgit Adam; Christopher Parow
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

9.  Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model.

Authors:  Fievos L Christofi; Minsoo Kim; Jacqueline E Wunderlich; Jianjing Xue; Zach Suntres; Arturo Cardounel; Najma H Javed; Jun Ge Yu; Iveta Grants; Helen J Cooke
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

10.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

View more
  59 in total

1.  Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities.

Authors:  Antonio M Scanu; Tim J Bull; Sara Cannas; Jeremy D Sanderson; Leonardo A Sechi; Giuseppe Dettori; Stefania Zanetti; John Hermon-Taylor
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

Review 2.  The role of probiotics in management of irritable bowel syndrome.

Authors:  Anna M Borowiec; Richard N Fedorak
Journal:  Curr Gastroenterol Rep       Date:  2007-10

3.  Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.

Authors:  Anna Lyra; Teemu Rinttilä; Janne Nikkilä; Lotta Krogius-Kurikka; Kajsa Kajander; Erja Malinen; Jaana Mättö; Laura Mäkelä; Airi Palva
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

4.  MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.

Authors:  QiQi Zhou; Wiley W Souba; Carlo M Croce; G Nicholas Verne
Journal:  Gut       Date:  2009-12-01       Impact factor: 23.059

5.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

6.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 7.  Public health significance of neuroticism.

Authors:  Benjamin B Lahey
Journal:  Am Psychol       Date:  2009 May-Jun

8.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

9.  Establishment of a Shigella sonnei human challenge model in Thailand.

Authors:  Ladaporn Bodhidatta; Punnee Pitisuttithum; Supat Chamnanchanant; Karen T Chang; Dilara Islam; Valai Bussaratid; Malabi M Venkatesan; Thomas L Hale; Carl J Mason
Journal:  Vaccine       Date:  2012-10-12       Impact factor: 3.641

10.  Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia.

Authors:  M M Walker; N J Talley; M Prabhakar; C J Pennaneac'h; P Aro; J Ronkainen; T Storskrubb; W S Harmsen; A R Zinsmeister; L Agreus
Journal:  Aliment Pharmacol Ther       Date:  2009-01-17       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.